Original fundamental research starts and ENDS here.
Sectors Tags Blog
VRTX
4 filings
Timeline Columns Start Research 8-K Categories
Showing: Other Clear filter
2025
Q1 1 filings
Mar
VX-264 Program Discontinued
$400M impairment charge for Q1 2025
8-K
2024
Q4 1 filings
Dec
FDA Approves ALYFTREK
ALYFTREK approved for cystic fibrosis, priced at $370,269 annually
8-K
Q3 1 filings
Aug
Headquarters Lease Extension
1.1M sq ft lease extended to June 2044
8-K
2023
Q4 1 filings
Dec
FDA Approves CASGEVY
Gene therapy for sickle cell disease, $2.2M wholesale price
8-K
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.